Every 10-Q that Lantheus Holdings, Inc (LNTH) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow LNTH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LNTH filings page.
Lantheus Holdings reported stronger profitability for the first half of 2026, with revenue of approximately $765.5 million and net income of $193.4 million, up from $151.7 million a year earlier. Diluted EPS rose to $2.91. Results include a $59.5 million gain from the January 1, 2026 sale of the SPECT business and a favorable $31.8 million reduction in contingent consideration liabilities.
Cash and cash equivalents increased to $593.3 million at June 30, 2026, with operating cash flow of $217.3 million and no borrowings under a $750.0 million revolving credit facility; the main debt is $575.0 million of 2.625% Convertible Senior Notes due 2027. Product mix is shifting as oncology revenue from PYLARIFY declined while Neuraceq neurology revenue reached $75.1 million and DEFINITY cardiology sales increased. The FDA issued a Complete Response Letter for LNTH-2501 (Octevy) due to third-party manufacturing-facility issues, which reduced the probability of certain milestone payments and lowered contingent consideration liabilities to $65.0 million.
Lantheus Holdings reported results for the three months ended March 31, 2026, showing modest revenue growth but sharply higher profit. Total revenues were $377.3 million, up slightly from $372.8 million a year earlier, as product sales of PYLARIFY, Neuraceq and DEFINITY drove most of the total.
Net income rose to $118.4 million from $72.9 million, helped by a $59.3 million gain on the sale of its SPECT business and an unrealized gain of $14.9 million on equity investments. Diluted earnings per share increased to $1.80 from $1.02, while operating income declined to $81.3 million as sales, marketing and R&D expenses increased.
Cash, cash equivalents and restricted cash climbed to $500.3 million, supported by strong operating cash flow of $125.1 million and cash proceeds from the SPECT divestiture. The company continues to carry $575.0 million of 2.625% Convertible Senior Notes due 2027 and ended the period with stockholders’ equity of $1.21 billion.
Lantheus Holdings (LNTH) reported Q3 2025 results. Revenue was $384.0 million and diluted EPS was $0.41 as operating income declined to $43.6 million, reflecting higher sales, G&A, and R&D expenses and a higher effective tax rate of 34.5%.
Revenue mix shifted: PYLARIFY was $240.6 million (down year over year), DEFINITY rose to $81.8 million, and Neuraceq contributed $20.4 million following the Life Molecular acquisition. Year-to-date operating cash flow reached $300.0 million, while investing cash outflows reflected acquisitions of Evergreen ($268.9 million) and Life Molecular ($309.0 million). The company repurchased about $201.2 million of common stock year to date.
Cash and cash equivalents were $382.0 million versus $912.8 million at year-end, with intangibles and goodwill increasing from recent deals. LNTH classified its SPECT business as held for sale, with $76.6 million of assets and $28.6 million of liabilities. The $575.0 million 2.625% convertible notes remain outstanding; the $750.0 million revolving credit facility had no borrowings.
Lantheus (LNTH) Q2-25 10-Q highlights:
- Revenue slipped 4% YoY to $378.0 M as PYLARIFY sales moderated (-8%) and TechneLite continued to decline ahead of the planned SPECT divestiture. Six-month revenue down 2% to $750.8 M.
- Gross margin held at 64% (241.0/378.0). Opex flat YoY; R&D down 25% as AZEDRA spend ended. Operating income fell 14% to $88.0 M, but lower unrealised equity losses and higher interest income lifted net income 27% to $78.8 M (dil. EPS $1.12).
- Six-month net income dropped 22% to $151.7 M as Q1 faced a sharp mark-to-market equity loss.
- Cash flow from ops was a solid $194.7 M, offset by $296.2 M investing cash outflow, chiefly the $269 M acquisition of radiotherapeutics CDMO Evergreen Theragnostics. Cash & equivalents fell to $695.6 M; net cash still ~>$120 M versus $575 M 2.625% converts.
- Balance sheet adds $116.2 M Evergreen goodwill and $215 M IPR&D; fair-valued contingent consideration booked at $43.0 M.
- SPECT business classified as held-for-sale (assets $73.4 M, liabilities $29.8 M) under agreement with SHINE; no impairment recorded.
- Shareholder returns: repurchased 1.3 M shares for $100 M in Q2; $200 M total under $250 M 2024 program. 68.0 M basic shares outstanding (-2% YoY).
- Leverage covenants remain comfortable (net leverage 0.6×); no borrowings under $750 M revolver.
Outlook: While topline softness persists near term, the Evergreen acquisition broadens manufacturing capacity and adds Octevy & CDMO revenue options; SPECT sale will further concentrate on high-growth PET oncology and diagnostics franchise.